Talk:WuXi AppTec
Appearance
![]() | Companies Start‑class Low‑importance | ||||||||||||||||
|
![]() | The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE. |
Updates to the article
Hi, as the declared COI editor for WuXi AppTec, I would like to suggest some updates to the article based on the company's activities in recent years. Please add:
- In the History section - In 2019, WuXi AppTec acquired Pharmapace, a clinical services company in San Diego.[1] In 2021, WuXi STA purchased a Bristol Myers Squibb drug product manufacturing facility in Switzerland,[2] WuXi AppTec acquired the UK-based R&D contract company, OXGENE,[3] and WuXi ATU opened a testing center in Philadelphia.[4]
Additionally, the different WuXi AppTec entities are inaccurate in the article. See this source to explain the rename and these entities under the WuXi AppTec umbrella. As far as I understand, based on the guidelines, this would be an uncontroversial edit for me to do. As it is a bit labor-intensive, I am happy to go in and do it myself with the community's approval.
References
- ^ Adams, Ben (8 May 2019). "China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering". fiercebiotech.com.
- ^ "WuXi STA completes acquisition of Bristol Myers Squibb manufacturing facility in Switzerland". 3 August 2021.
- ^ "OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition by WuXi AppTec". genedgenews.com. 3 March 2021.
- ^ MacDonald, Gareth (7 December 2021). "WuXi ATU opens cell and gene therapy testing center". bioprocessintl.com.
Thank you very much.AM WuXi (talk) 14:46, 6 December 2023 (UTC)